Practical efficacy of olmesartan versus azilsartan in patients with hypertension: A multicenter randomized-controlled trial (MUSCAT-4 study)

Yuki Kakio, Haruhito Adam Uchida, Ryoko Umebayashi, Hidemi Takeuchi, Yuka Okuyama, Yoshihisa Hanayama, Jun Wada

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background Olmesartan and azilsartan, angiotensin II receptor blockers (ARBs), are expected to decrease blood pressure more than the other ARBs. We conducted randomized-controlled trials to compare the practical efficacy of olmesartan with azilsartan. Methods Eighty-four patients treated with the conventional ARBs for more than 3 months were assigned randomly to receive either 20 mg of olmesartan (olmesartan medoxomil, OL group) or 20 mg of azilsartan (azilsartan, not azilsartan medoxomil, AZ group) once daily for 16 weeks. The practical efficacy on blood pressure was compared between the OL and AZ groups. Results Office blood pressure of both groups decreased significantly (OL group: 152/86-141/79 mmHg, P<0.05, AZ group: 149/83-135/75 mmHg; P<0.05). Diastolic home blood pressure in the AZ group decreased significantly (79±9-74±7 mmHg; P<0.05), but not in the OL group (79±11-75±10 mmHg; P=0.068). However, there were no significant differences between the groups. The dosage of olmesartan and azilsartan increased significantly and slightly for 16 weeks (OL group: 20.3-23.1 mg; P<0.05, AZ group: 20.5-23.2 mg; P<0.05), without a significant difference between groups. Furthermore, there were no significant differences in renal function, lipid profiles, brain natriuretic peptide, soluble fms-like tyrosine kinase-1, and urinary L-type fatty acid-binding protein between the two groups. Conclusion Both olmesartan and azilsartan equally reduced blood pressures. Both olmesartan and azilsartan showed a renoprotective effect and were well tolerated without any major adverse events.

Original languageEnglish
Pages (from-to)59-67
Number of pages9
JournalBlood Pressure Monitoring
Volume22
Issue number2
DOIs
Publication statusPublished - 2017

Fingerprint

Randomized Controlled Trials
Hypertension
Angiotensin Receptor Antagonists
Blood Pressure
Vascular Endothelial Growth Factor Receptor-1
Fatty Acid-Binding Proteins
Brain Natriuretic Peptide
azilsartan
olmesartan
Kidney
Lipids

Keywords

  • angiotensin II receptor blocker
  • azilsartan
  • hypertension
  • olmesartan
  • renoprotective effect

ASJC Scopus subject areas

  • Internal Medicine
  • Assessment and Diagnosis
  • Cardiology and Cardiovascular Medicine
  • Advanced and Specialised Nursing

Cite this

Practical efficacy of olmesartan versus azilsartan in patients with hypertension : A multicenter randomized-controlled trial (MUSCAT-4 study). / Kakio, Yuki; Uchida, Haruhito Adam; Umebayashi, Ryoko; Takeuchi, Hidemi; Okuyama, Yuka; Hanayama, Yoshihisa; Wada, Jun.

In: Blood Pressure Monitoring, Vol. 22, No. 2, 2017, p. 59-67.

Research output: Contribution to journalArticle

@article{342baa09c659439096b894bf0fabb146,
title = "Practical efficacy of olmesartan versus azilsartan in patients with hypertension: A multicenter randomized-controlled trial (MUSCAT-4 study)",
abstract = "Background Olmesartan and azilsartan, angiotensin II receptor blockers (ARBs), are expected to decrease blood pressure more than the other ARBs. We conducted randomized-controlled trials to compare the practical efficacy of olmesartan with azilsartan. Methods Eighty-four patients treated with the conventional ARBs for more than 3 months were assigned randomly to receive either 20 mg of olmesartan (olmesartan medoxomil, OL group) or 20 mg of azilsartan (azilsartan, not azilsartan medoxomil, AZ group) once daily for 16 weeks. The practical efficacy on blood pressure was compared between the OL and AZ groups. Results Office blood pressure of both groups decreased significantly (OL group: 152/86-141/79 mmHg, P<0.05, AZ group: 149/83-135/75 mmHg; P<0.05). Diastolic home blood pressure in the AZ group decreased significantly (79±9-74±7 mmHg; P<0.05), but not in the OL group (79±11-75±10 mmHg; P=0.068). However, there were no significant differences between the groups. The dosage of olmesartan and azilsartan increased significantly and slightly for 16 weeks (OL group: 20.3-23.1 mg; P<0.05, AZ group: 20.5-23.2 mg; P<0.05), without a significant difference between groups. Furthermore, there were no significant differences in renal function, lipid profiles, brain natriuretic peptide, soluble fms-like tyrosine kinase-1, and urinary L-type fatty acid-binding protein between the two groups. Conclusion Both olmesartan and azilsartan equally reduced blood pressures. Both olmesartan and azilsartan showed a renoprotective effect and were well tolerated without any major adverse events.",
keywords = "angiotensin II receptor blocker, azilsartan, hypertension, olmesartan, renoprotective effect",
author = "Yuki Kakio and Uchida, {Haruhito Adam} and Ryoko Umebayashi and Hidemi Takeuchi and Yuka Okuyama and Yoshihisa Hanayama and Jun Wada",
year = "2017",
doi = "10.1097/MBP.0000000000000229",
language = "English",
volume = "22",
pages = "59--67",
journal = "Blood Pressure Monitoring",
issn = "1359-5237",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Practical efficacy of olmesartan versus azilsartan in patients with hypertension

T2 - A multicenter randomized-controlled trial (MUSCAT-4 study)

AU - Kakio, Yuki

AU - Uchida, Haruhito Adam

AU - Umebayashi, Ryoko

AU - Takeuchi, Hidemi

AU - Okuyama, Yuka

AU - Hanayama, Yoshihisa

AU - Wada, Jun

PY - 2017

Y1 - 2017

N2 - Background Olmesartan and azilsartan, angiotensin II receptor blockers (ARBs), are expected to decrease blood pressure more than the other ARBs. We conducted randomized-controlled trials to compare the practical efficacy of olmesartan with azilsartan. Methods Eighty-four patients treated with the conventional ARBs for more than 3 months were assigned randomly to receive either 20 mg of olmesartan (olmesartan medoxomil, OL group) or 20 mg of azilsartan (azilsartan, not azilsartan medoxomil, AZ group) once daily for 16 weeks. The practical efficacy on blood pressure was compared between the OL and AZ groups. Results Office blood pressure of both groups decreased significantly (OL group: 152/86-141/79 mmHg, P<0.05, AZ group: 149/83-135/75 mmHg; P<0.05). Diastolic home blood pressure in the AZ group decreased significantly (79±9-74±7 mmHg; P<0.05), but not in the OL group (79±11-75±10 mmHg; P=0.068). However, there were no significant differences between the groups. The dosage of olmesartan and azilsartan increased significantly and slightly for 16 weeks (OL group: 20.3-23.1 mg; P<0.05, AZ group: 20.5-23.2 mg; P<0.05), without a significant difference between groups. Furthermore, there were no significant differences in renal function, lipid profiles, brain natriuretic peptide, soluble fms-like tyrosine kinase-1, and urinary L-type fatty acid-binding protein between the two groups. Conclusion Both olmesartan and azilsartan equally reduced blood pressures. Both olmesartan and azilsartan showed a renoprotective effect and were well tolerated without any major adverse events.

AB - Background Olmesartan and azilsartan, angiotensin II receptor blockers (ARBs), are expected to decrease blood pressure more than the other ARBs. We conducted randomized-controlled trials to compare the practical efficacy of olmesartan with azilsartan. Methods Eighty-four patients treated with the conventional ARBs for more than 3 months were assigned randomly to receive either 20 mg of olmesartan (olmesartan medoxomil, OL group) or 20 mg of azilsartan (azilsartan, not azilsartan medoxomil, AZ group) once daily for 16 weeks. The practical efficacy on blood pressure was compared between the OL and AZ groups. Results Office blood pressure of both groups decreased significantly (OL group: 152/86-141/79 mmHg, P<0.05, AZ group: 149/83-135/75 mmHg; P<0.05). Diastolic home blood pressure in the AZ group decreased significantly (79±9-74±7 mmHg; P<0.05), but not in the OL group (79±11-75±10 mmHg; P=0.068). However, there were no significant differences between the groups. The dosage of olmesartan and azilsartan increased significantly and slightly for 16 weeks (OL group: 20.3-23.1 mg; P<0.05, AZ group: 20.5-23.2 mg; P<0.05), without a significant difference between groups. Furthermore, there were no significant differences in renal function, lipid profiles, brain natriuretic peptide, soluble fms-like tyrosine kinase-1, and urinary L-type fatty acid-binding protein between the two groups. Conclusion Both olmesartan and azilsartan equally reduced blood pressures. Both olmesartan and azilsartan showed a renoprotective effect and were well tolerated without any major adverse events.

KW - angiotensin II receptor blocker

KW - azilsartan

KW - hypertension

KW - olmesartan

KW - renoprotective effect

UR - http://www.scopus.com/inward/record.url?scp=85009383175&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85009383175&partnerID=8YFLogxK

U2 - 10.1097/MBP.0000000000000229

DO - 10.1097/MBP.0000000000000229

M3 - Article

C2 - 28079534

AN - SCOPUS:85009383175

VL - 22

SP - 59

EP - 67

JO - Blood Pressure Monitoring

JF - Blood Pressure Monitoring

SN - 1359-5237

IS - 2

ER -